This Deal Is No Dog

Eli Lilly's (NYSE: LLY  ) latest pact with Johnson & Johnson (NYSE: JNJ  ) is an animal of a deal -- but only in the literal, not figurative, way.

Eli Lilly is purchasing Johnson & Johnson's European-based animal-health business. The deal will bring about 50 animal-health products to Eli Lilly's Elanco unit.

There wasn't a manufacturing plant as part of the deal and terms weren't disclosed, so it's likely a minor trade for the two companies with multibillion dollars' worth of sales. It's safe to say the deal by itself isn't going to do much to make up for the blockbuster drugs Lilly is about to lose.

But every little bit helps. Lilly picked up a suite of European animal-health products and a manufacturing plant to produce them from Pfizer (NYSE: PFE  ) last year. Adding the products from Johnson & Johnson should help operational efficiencies. For the most part, the more products a sales force has to offer, the better.

And Eli Lilly can use all the beefing up it can get. The animal-health division is in a stall next to some tough competition as Merck (NYSE: MRK  ) and sanofi-aventis (NYSE: SNY  ) bring their two animal-health divisions together. The new joint venture is a combination of Merck and Sanofi's old joint venture, Merial, plus Schering-Plough's animal-health division, Intervet, that Merck acquired in 2009.

Lilly might get a chance to grab a few more products when Merial and Intervet come together. The closing of the deal seems to be taking longer than expected, which I'm guessing is because the companies are in negotiations with antitrust regulators to figure out exactly what products they'll need to divest of. That's how it got the products from Pfizer last year.

We might have to start calling Eli Lilly a vulture – figuratively, of course.

Interested in keeping track of Eli Lilly? Click here to add it to My Watchlist, which will help you keep track of all our Foolish analysis on Eli Lilly.

Johnson & Johnson and Pfizer are Motley Fool Inside Value selections. Johnson & Johnson is a Motley Fool Income Investor pick. Motley Fool Options has recommended a diagonal call position on Johnson & Johnson. The Fool owns shares of Johnson & Johnson. Motley Fool Alpha owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1457963, ~/Articles/ArticleHandler.aspx, 11/27/2014 11:26:53 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement